Health
Animal data supports efficacy of baricitinib vs SARS-COV-2 – News-Medical.Net
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 202…
The high burden of disease caused by the COVID-19 pandemic has led to much research on effective ways to mitigate the health, social, and economic impact of the spread of the infection. A recent study published on the preprint server bioRxiv* in September 2020 reports on the characteristics of the drug baricitinib when used as monotherapy to treat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
Inflammatory Responses in COVID-19
Severe COVID-19 is associated with high fever, non-…
-
Noosa News20 hours agoMeasles alert: Australia Zoo, Hospital ED, Sushi Hub, Holey Moley Mini Golf and train stations among QLD infection sites
-
General8 hours agoPoliticians asked how to Trump-proof Australia’s fragile economy on Q+A
-
Business20 hours ago1 ASX dividend stock down 43% I’d buy right now
-
Noosa News22 hours agoNSW farmer calls for hunting buffer zones after bullets hit property